Retracted: Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study
- PMID: 38549982
- PMCID: PMC10977187
- DOI: 10.1155/2024/9785671
Retracted: Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study
Abstract
[This retracts the article DOI: 10.1155/2020/3208391.].
Copyright © 2024 BioMed Research International.
Retraction of
-
Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.Biomed Res Int. 2020 May 2;2020:3208391. doi: 10.1155/2020/3208391. eCollection 2020. Biomed Res Int. 2020. Retraction in: Biomed Res Int. 2024 Mar 20;2024:9785671. doi: 10.1155/2024/9785671. PMID: 32461977 Free PMC article. Retracted.
References
-
- Zhang M., Li L., Zhang S., et al. Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinoma: A Real-World Study. BioMed Research International . 2020;2020:9. doi: 10.1155/2020/3208391.3208391 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
